JP2020524993A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020524993A5 JP2020524993A5 JP2019568601A JP2019568601A JP2020524993A5 JP 2020524993 A5 JP2020524993 A5 JP 2020524993A5 JP 2019568601 A JP2019568601 A JP 2019568601A JP 2019568601 A JP2019568601 A JP 2019568601A JP 2020524993 A5 JP2020524993 A5 JP 2020524993A5
- Authority
- JP
- Japan
- Prior art keywords
- synthetic
- cron
- existent
- nucleic acid
- orf1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022187239A JP2023010961A (ja) | 2017-06-13 | 2022-11-24 | クロンを含む組成物及びその使用 |
| JP2024069618A JP2024087003A (ja) | 2017-06-13 | 2024-04-23 | クロンを含む組成物及びその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762518898P | 2017-06-13 | 2017-06-13 | |
| US62/518,898 | 2017-06-13 | ||
| US201762597387P | 2017-12-11 | 2017-12-11 | |
| US62/597,387 | 2017-12-11 | ||
| US201862676730P | 2018-05-25 | 2018-05-25 | |
| US62/676,730 | 2018-05-25 | ||
| PCT/US2018/037379 WO2018232017A1 (en) | 2017-06-13 | 2018-06-13 | Compositions comprising curons and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022187239A Division JP2023010961A (ja) | 2017-06-13 | 2022-11-24 | クロンを含む組成物及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020524993A JP2020524993A (ja) | 2020-08-27 |
| JP2020524993A5 true JP2020524993A5 (https=) | 2021-07-26 |
Family
ID=62846247
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568601A Withdrawn JP2020524993A (ja) | 2017-06-13 | 2018-06-13 | クロンを含む組成物及びその使用 |
| JP2022187239A Withdrawn JP2023010961A (ja) | 2017-06-13 | 2022-11-24 | クロンを含む組成物及びその使用 |
| JP2024069618A Pending JP2024087003A (ja) | 2017-06-13 | 2024-04-23 | クロンを含む組成物及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022187239A Withdrawn JP2023010961A (ja) | 2017-06-13 | 2022-11-24 | クロンを含む組成物及びその使用 |
| JP2024069618A Pending JP2024087003A (ja) | 2017-06-13 | 2024-04-23 | クロンを含む組成物及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20200123203A1 (https=) |
| EP (1) | EP3638797A1 (https=) |
| JP (3) | JP2020524993A (https=) |
| KR (2) | KR20200038236A (https=) |
| CN (1) | CN111108208A (https=) |
| AU (2) | AU2018285860A1 (https=) |
| BR (1) | BR112019026226A2 (https=) |
| CA (1) | CA3066750A1 (https=) |
| IL (1) | IL271275B1 (https=) |
| MX (2) | MX2019015018A (https=) |
| WO (1) | WO2018232017A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| US11166996B2 (en) | 2018-12-12 | 2021-11-09 | Flagship Pioneering Innovations V, Inc. | Anellovirus compositions and methods of use |
| KR20210131309A (ko) * | 2018-12-12 | 2021-11-02 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 분비형 치료 양식을 운반하기 위한 아넬로좀 |
| BR112021011124A2 (pt) * | 2018-12-12 | 2022-03-15 | Flagship Pioneering Innovations V Inc | Anelossomos e métodos de uso |
| JP2022513459A (ja) * | 2018-12-12 | 2022-02-08 | フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド | タンパク質代替治療モダリティを送達するためのアネロソーム |
| WO2020123753A2 (en) * | 2018-12-12 | 2020-06-18 | Flagship Pioneering Innovations V, Inc. | Anellosomes for delivering intracellular therapeutic modalities |
| WO2020252455A1 (en) | 2019-06-13 | 2020-12-17 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| WO2021016075A1 (en) | 2019-07-19 | 2021-01-28 | Flagship Pioneering Innovations Vi, Llc | Recombinase compositions and methods of use |
| CN116034160A (zh) * | 2020-06-12 | 2023-04-28 | 旗舰先锋创新V股份有限公司 | 杆状病毒表达系统 |
| AU2021288320A1 (en) * | 2020-06-12 | 2023-01-19 | Flagship Pioneering Innovations V, Inc. | Tandem anellovirus constructs |
| JP2023530451A (ja) * | 2020-06-17 | 2023-07-18 | フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド | アネロウイルスを同定し及び特徴付ける方法並びにその使用 |
| EP4185600A4 (en) | 2020-07-24 | 2024-12-04 | The General Hospital Corporation | Enhanced virus-like particles and methods of use thereof for delivery to cells |
| WO2022026446A1 (en) * | 2020-07-27 | 2022-02-03 | Wisconsin Alumni Research Foundation | Methods of making unbiased phage libraries |
| EP4267157A4 (en) * | 2020-12-23 | 2025-05-07 | Flagship Pioneering Innovations V, Inc. | IN VITRO ASSEMBLY OF ANELLOVIRUS CAPSIDS WITH RNA |
| KR20230146560A (ko) * | 2021-02-08 | 2023-10-19 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 하이브리드 aav-아넬로벡터 |
| US20250027107A1 (en) * | 2021-10-18 | 2025-01-23 | Flagship Pioneering Innovations Vii, Llc | Dna compositions and related methods |
| TW202430215A (zh) | 2022-12-14 | 2024-08-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 用於將治療劑遞送至骨之組成物和方法 |
| WO2025194138A1 (en) | 2024-03-14 | 2025-09-18 | Tessera Therapeutics, Inc. | St1cas9 compositions and methods for modulating a genome |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR751473A (fr) * | 1932-06-01 | 1933-09-04 | Poste d'incendie | |
| AU722624B2 (en) | 1996-09-06 | 2000-08-10 | Trustees Of The University Of Pennsylvania, The | An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase |
| US6693086B1 (en) | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| US6395472B1 (en) * | 1999-02-05 | 2002-05-28 | Abbott Laboratories | Methods of utilizing the TT virus |
| US7901708B2 (en) | 2002-06-28 | 2011-03-08 | Protiva Biotherapeutics, Inc. | Liposomal apparatus and manufacturing methods |
| ES2559828T3 (es) | 2003-07-16 | 2016-02-16 | Protiva Biotherapeutics Inc. | ARN de interferencia encapsulado en lípidos |
| NZ592917A (en) | 2003-09-15 | 2012-12-21 | Protiva Biotherapeutics Inc | Stable polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates |
| AU2005222965B8 (en) | 2004-03-15 | 2010-07-01 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| US7799565B2 (en) | 2004-06-07 | 2010-09-21 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering RNA |
| US7745651B2 (en) | 2004-06-07 | 2010-06-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
| JP2008512350A (ja) | 2004-07-01 | 2008-04-24 | イェール ユニバーシティ | 標的化され、そして高密度で薬物が負荷されるポリマー性物質 |
| WO2007048046A2 (en) | 2005-10-20 | 2007-04-26 | Protiva Biotherapeutics, Inc. | Sirna silencing of filovirus gene expression |
| US8101741B2 (en) | 2005-11-02 | 2012-01-24 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
| US7915399B2 (en) | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
| AU2009238175C1 (en) | 2008-04-15 | 2023-11-30 | Arbutus Biopharma Corporation | Novel lipid formulations for nucleic acid delivery |
| AU2009336191B2 (en) | 2008-12-18 | 2017-08-24 | Novo Nordisk A/S | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
| US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
| US8603966B2 (en) | 2009-02-27 | 2013-12-10 | The Administrators Of The Tulane Educational Fund | Amino acid-based compounds, their methods of use, and methods of screening |
| US8236943B2 (en) | 2009-07-01 | 2012-08-07 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein B |
| ES2613498T3 (es) | 2009-07-01 | 2017-05-24 | Protiva Biotherapeutics Inc. | Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos |
| US9676828B2 (en) * | 2010-06-23 | 2017-06-13 | Deutsches Krebsforschungszentrum | Rearranged TT virus molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity |
| BR112013026199A2 (pt) * | 2011-04-15 | 2017-11-07 | Compugen Ltd | polipeptídeo isolado, proteína de fusão, sequência de ácidos nucleicos, vetor de expressão ou um vírus, célula recombinante, método de produção de um polipeptídeo com ectodomínio solúvel lsr, ou seu fragmento ou proteína de fusão, composição farmacêutica, uso de um anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, uso do anticorpo ou do fragmento de ligação ao antígeno, uso de qualquer um de um polipeptídeo isolado, método de regulação por cima de citocinas, indução da expansão de células t, promoção da imunidade de células t específica antigênica e promoção da ativação das células t cd4+ e/ou cd8+ em um sujeito, método para potenciação de uma resposta imune secundária a um antígeno em um paciente, método de uso de pelo menos um de: um polipeptídeo isolado, método para tratamento ou prevenção de uma condição relacionada com o sistema imune, método para tratamento ou prevenção de uma doença infecciosa, método para diagnóstico de uma doença em um sujeito, método de produção de um polipeptídeo com ectodomínio solúvel tmem25, vsig10, ly6g6f, ou seu fragmento ou proteína de fusão, anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, método de imunoterapia em um paciente e método para combinação de vacinação terapêutica com um antígeno em conjunto com a administração de qualquer um de um polipeptídeo |
| EP3241902B1 (en) | 2012-05-25 | 2018-02-28 | The Regents of The University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| EP4357457B1 (en) | 2012-10-23 | 2024-10-16 | Toolgen Incorporated | Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof |
| AU2013359262C1 (en) | 2012-12-12 | 2021-05-13 | Massachusetts Institute Of Technology | CRISPR-Cas component systems, methods and compositions for sequence manipulation |
| CN105121648B (zh) | 2012-12-12 | 2021-05-07 | 布罗德研究所有限公司 | 用于序列操纵的系统、方法和优化的指导组合物的工程化 |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| CA2894684A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of improved crispr-cas systems, methods and enzyme compositions for sequence manipulation in eukaryotes |
| DK2931898T3 (en) | 2012-12-12 | 2016-06-20 | Massachusetts Inst Technology | CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS |
| EP3470089A1 (en) * | 2013-12-12 | 2019-04-17 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
-
2018
- 2018-06-12 IL IL271275A patent/IL271275B1/en unknown
- 2018-06-13 EP EP18738411.0A patent/EP3638797A1/en active Pending
- 2018-06-13 MX MX2019015018A patent/MX2019015018A/es unknown
- 2018-06-13 KR KR1020207000972A patent/KR20200038236A/ko not_active Ceased
- 2018-06-13 AU AU2018285860A patent/AU2018285860A1/en not_active Abandoned
- 2018-06-13 KR KR1020257004957A patent/KR20250028508A/ko active Pending
- 2018-06-13 CA CA3066750A patent/CA3066750A1/en active Pending
- 2018-06-13 BR BR112019026226-1A patent/BR112019026226A2/pt unknown
- 2018-06-13 WO PCT/US2018/037379 patent/WO2018232017A1/en not_active Ceased
- 2018-06-13 JP JP2019568601A patent/JP2020524993A/ja not_active Withdrawn
- 2018-06-13 US US16/622,146 patent/US20200123203A1/en not_active Abandoned
- 2018-06-13 CN CN201880051296.6A patent/CN111108208A/zh active Pending
-
2019
- 2019-03-27 US US16/366,571 patent/US20190211361A1/en not_active Abandoned
- 2019-12-11 MX MX2023011657A patent/MX2023011657A/es unknown
-
2020
- 2020-01-16 US US16/744,363 patent/US20200385757A1/en not_active Abandoned
-
2022
- 2022-07-15 US US17/812,896 patent/US20230279423A1/en not_active Abandoned
- 2022-11-24 JP JP2022187239A patent/JP2023010961A/ja not_active Withdrawn
-
2024
- 2024-04-23 JP JP2024069618A patent/JP2024087003A/ja active Pending
-
2025
- 2025-01-24 AU AU2025200497A patent/AU2025200497A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020524993A5 (https=) | ||
| US11446344B1 (en) | Anellovirus compositions and methods of use | |
| US20120009221A1 (en) | Transfection of blood cells with mrna for immune stimulation and gene therapy | |
| CN111108208A (zh) | 包含愈合子的组合物及其用途 | |
| JP2022512395A (ja) | 分泌治療モダリティを送達するためのアネロソーム | |
| US12220456B2 (en) | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids | |
| JP2007511216A (ja) | 変異ウイルス | |
| CN110393791B (zh) | hnRNPA2B1的抗感染作用及其应用 | |
| JP2019501661A5 (https=) | ||
| WO2019080537A1 (zh) | 包含溶瘤病毒和car-nk细胞的治疗剂及应用、药盒、治疗肿瘤和/或癌症的方法 | |
| KR20210131310A (ko) | 아넬로좀 및 사용 방법 | |
| JP2022513459A (ja) | タンパク質代替治療モダリティを送達するためのアネロソーム | |
| JP2022514501A (ja) | 細胞内治療モダリティを送達するためのアネロソーム | |
| WO2021253733A1 (en) | Construct and use thereof | |
| CN119736261A (zh) | 溶瘤病毒及其应用 | |
| CN114127301B (zh) | 用于治疗肿瘤的药物组合物、药盒和方法 | |
| JP7047238B2 (ja) | 安全性及び抗がん効果が改善した腫瘍溶解性ウイルス | |
| US11524047B2 (en) | Pharmaceutical compositions for preventing or treating pulmonary metastasis of cancer including CHI3L1 inhibitor as active ingredient | |
| CN115989321B (zh) | 病毒制剂、用于配制病毒制剂的溶液及其用途 | |
| CN111041001B (zh) | 治疗kras突变型肿瘤的安全型柯萨奇病毒及其药物组合物 | |
| JPWO2005103237A1 (ja) | 組換え単純ヘルペスウイルスの作製方法 | |
| Ni et al. | Antitumor efficacy of CRISPR/Cas9–engineered ICP6 mutant herpes simplex viruses in a mouse xenograft model for lung adenocarcinoma | |
| US20240050580A1 (en) | Compositions targeting tumor associated macrophages and methods using same | |
| JPWO2020123816A5 (https=) | ||
| US20170319639A1 (en) | Oncolytic viruses & methods of use thereof |